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Background: Complicated grief (CG) is a bereavement‐specific syndrome distinct from
but commonly comorbid with posttraumatic stress disorder (PTSD). While bereavement
is common among military personnel (Simon et al., 2018), there is little research on the
impact of CG comorbidity on PTSD treatment outcomes.
Methods: To evaluate the impact of comorbid CG on PTSD treatment outcomes we
analyzed data from a randomized trial comparing prolonged exposure, sertraline, and
their combination in veterans with a primary diagnosis of combat‐related PTSD (n = 194).
Assessment of PTSD, trauma‐related guilt, functional impairment, and suicidal ideation
and behavior occurred at baseline and weeks 6, 12, and 24 during the 24‐week trial.
Results: CG was associated with lower PTSD treatment response (odds ratio
(OR) = 0.29, 95% confidence interval (CI) [0.12, 0.69], p = 0.005) and remission
(OR= 0.28, 95% CI [0.11, 0.71], p = 0.007). Those with CG had greater severity of PTSD
(p = 0.005) and trauma‐related guilt (<0.001) at baseline and endpoint. In addition, those
with CG were more likely to experience suicidal ideation during the study (CG: 35%, 14/
40 vs. no CG 15%, 20/130; OR= 3.01, 95% CI [1.29, 7.02], p =0.011).
Conclusions: Comorbid CG is associated with elevated PTSD severity and
independently associated with poorer endpoint treatment outcomes in veterans
with combat‐related PTSD, suggesting that screening and additional intervention for
CG may be needed.
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1 | INTRODUCTION
Loss of a close attachment is among life’s greatest stressors (Holmes
& Rahe, 1967). Although the distress and disruption of grief subsides
over time for most bereaved adults, approximately 10% experience a
prolonged, impairing grief reaction (Lundorff, Holmgren, Zachariae,
Farver‐Vestergaard, & O’Connor, 2017). This grief‐related condition
was included in the ICD‐11 (World Health Organization, 2018) and
provisionally in the DSM‐5 (American Psychiatric Association, 2013)
with different names. Consistent with our prior work and that of
many others (e.g., Horowitz et al., 1997; Shear et al., 2011; Simon
et al., 2018), we will refer to this syndrome as complicated grief (CG).
Although precise diagnostic criteria are still being refined (Mauro
et al., 2017; Prigerson & Maciejewski, 2017; Reynolds, Cozza, &
Shear, 2017), there is broad agreement that core CG symptoms
include intense yearning for the deceased, emotional pain, and
preoccupation with thoughts about the death or the deceased
(American Psychiatric Association, 2013; Prigerson et al., 2009;
Simon et al., 2011; World Health Organization, 2018). Individuals
with CG may also experience difficulty accepting the death or
planning for the future, role and identity confusion, feeling life is
unbearable without the deceased, avoidance of reminders of the loss,
and in some cases a wish to die to join the deceased (Mauro et al.,
2016; Simon et al., 2011).
CG is conceptualized as persistent symptoms of both traumatic
distress and separation distress due to the loss of an important
attachment (Shear et al., 2011; Simon et al., 2011). Notably, attachment
related CG symptoms, such as yearning, are not observed in other
disorders that may follow bereavement, such as posttraumatic stress
disorder (PTSD) or major depressive disorder (MDD), supporting its
designation as a distinct post‐loss condition (e.g., Boelen & van den
Bout, 2005; Maercker & Lalor, 2012; Simon, 2012). Nonetheless, CG
often co‐occurs with mood, anxiety, and trauma related disorders such
as PTSD, and the presence of comorbidity is associated with greater CG
severity and greater functional impairment (Kristensen, Weisaeth,
Hussain, & Heir, 2015; Marques et al., 2013; Simon et al., 2007; Sung
et al., 2011). CG also shares features with other stressor‐related
conditions (e.g., PTSD and depression), including emotional distress,
avoidance, and guilt (American Psychiatric Association, 2013; Li,
Tendeiro, & Stroebe, 2018).
CG comorbidity with PTSD may be especially relevant for military
personnel, given the high risk for exposure to traumatic events as
well as significant, sudden, and violent losses (e.g., Toblin et al., 2012;
Wisco et al., 2014). A recent study in a military mental health clinic
found 43.5% of outpatients were impacted by a significant loss,
nearly half (46.1%) of whom exhibited clinically significant CG
symptoms (Delaney, Holloway, Miletich, Webb‐Murphy, & Lanouette,
2017). Losses during deployment, especially the loss of a fellow
service member (FSM), were associated with greater CG symptom
severity than other types of losses. Similarly, in a large sample of
post‐9/11 treatment‐seeking veterans, over 80% reported a sig-
nificant loss, and 30% exhibited clinically significant CG symptoms
(Charney et al., 2018). In this sample, CG was associated with more
severe PTSD and reduced quality of life. Previous studies of veterans
suggest that guilt may play a particularly important role when there
is a loss of a FSM, in part due to the nature of the special bonds
formed within military units as well as the potential responsibility for
decisions that can result in death in combat settings (Lee, Scragg, &
Turner, 2001; Litz et al., 2009; Nazarov et al., 2015). Guilt has also
been clearly associated with CG, including feelings of responsibility
for the death, guilt about one’s behavior toward the deceased in life,
or the very fact of living when the deceased person is not (survivor
guilt; e.g., see Li et al., 2018).
Our research group recently reported primary results of a
randomized controlled trial comparing prolonged exposure (PE),
sertraline, and their combination for combat‐related PTSD in a large
sample of post 9/11 veterans (Rauch, Simon, et al., 2018a, Rauch,
Kim, et al., 2018b). Although participants in all three treatment arms
improved significantly, no significant difference in PTSD symptom
change by treatment assignment was found (Rauch, Simon, et al.,
2018a). The correlates of CG comorbidity were examined in this
study sample at baseline (Simon et al., 2018). Most participants (79%)
reported a significant death, and 31% exhibited clinically significant
CG symptoms. Notably, those who had lost a FSM (47%) exhibited a
significantly higher rate of CG (41%) than those reporting other
losses (17%), suggesting this type of loss may be particularly
challenging for service members and veterans. CG was associated
with greater functional impairment, trauma‐related guilt, and lifetime
suicide attempts. These data are consistent with prior research
supporting an association of CG with functional impairment
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independent of other disorders including PTSD (e.g., Kristensen et al.,
2015; Marques et al., 2013). Similarly, suicidal thoughts have been
commonly reported in treatment seeking CG samples (Shear et al.,
2016; Shear, Wang, Skritskaya, Mauro, & Ghesquiere, 2014) and in
prospective CG research. This includes a study demonstrating an
eightfold risk of high suicidal ideation and behaviors even after
controlling for depression and PTSD (Latham & Prigerson, 2004).
Given the high prevalence and burden of comorbid CG and PTSD,
screening for loss and CG is recommended in military mental health
settings, but is not yet routinely implemented (Delaney et al., 2017).
This could be, in part, due to our limited understanding of the impact
of CG on PTSD outcomes. To our knowledge, no study has examined
the impact of comorbid CG symptoms on PTSD treatment outcomes
in individuals receiving PE or an antidepressant such as sertraline,
both recommended evidence‐based treatments for PTSD (e.g.,
American Psychological Association, 2017; Management of Posttrau-
matic Stress Disorder Work Group, 2017). Such examination is
particularly relevant to military populations, as comorbid PTSD and
CG are common and impairing.
The present study thus aimed to examine the impact of co‐
occurring CG on PTSD treatment outcomes in a sample of post 9/11
veterans with a primary diagnosis of combat‐related PTSD. The study
data were collected as part of a larger comparative effectiveness trial
comparing the efficacy of PE, sertraline, versus their combination in
the treatment of PTSD for this population (Rauch, Kim, et al., 2018b),
and builds upon the baseline findings reported recently by Simon
et al (2018). We hypothesized that comorbid CG would be associated
with poorer outcomes as indicated by (a) higher PTSD symptoms,
trauma‐related guilt, suicidal ideation, and functional impairment at
posttreatment, (b) lower PTSD response rate, and (c) lower PTSD
remission rates than those without CG, even after adjusting for
baseline differences in PTSD symptom severity. We further
hypothesized that this impact on treatment outcomes would be




This study was a planned secondary analysis of a multicenter clinical
trial funded by the Department of Defense (W81XWH‐11‐1‐0073).
Procedures were approved by site IRBs and DOD Human Research
Protection Office (HRPO), and registered at ClinicalTrials.gov
(NCT01524133). All participants were randomized to one of three
active evidence‐based PTSD treatment arms: PE + pill placebo,
sertraline (an FDA approved serotonin selective reuptake inhibitor) +
an enhanced medication management (EMM) protocol administered
by the pharmacotherapist, or PE + sertraline. Detailed methods and
primary results have been published (Rauch, Simon, et al., 2018a,
Rauch, Kim, et al., 2018b). Briefly, participants were 223 veterans or
service members with a primary diagnosis of combat‐related PTSD
who served in Iraq/Afghanistan wars in the United States military,
and 149 completed the 24‐week study. The primary modified intent‐
to‐treat analyses examined the 207 randomized participants who
received the study pills at least once. Our final sample consisted of
the subset of the modified intent‐to‐treat sample who completed a
loss cover sheet (indicating the presence or absence of a loss at
baseline) and the Inventory of Complicated Grief (ICG; Prigerson et al.,
1995: n = 194); 13 subjects (6%) were excluded for noncompletion.
2.2 | Measures
The primary outcome measure was the Clinician‐Administered PTSD
Scale (CAPS) for DSM‐IV (Blake et al., 1995), with diagnosis based on a
score of 50 or higher and PTSD present for at least 3 months. The
CAPS is commonly used to assess PTSD intensity, frequency, and
severity (Blake et al., 1995; Weathers, Keane, & Davidson, 2001). It
has a total score range from 0 to 272, where higher scores indicate
more severe PTSD symptoms. CAPS were administered by raters
certified by the standard process of the National Center for PTSD.
PTSD treatment response was defined as ≥50% CAPS reduction, and
remission was defined as CAPS of 35 or less; all definitions were
based on Week 24 or last observed CAPS up to Week 24. Comorbid
depression was assessed with the MINI International Neuropsychiatric
Interview (MINI) for DSM‐IV version 5.0 (Sheehan et al., 1998).
Grief symptoms were measured using the Inventory of Compli-
cated Grief (ICG; Prigerson et al., 1995), a 19‐item self‐report form
with each item rated from 0 (not at all) to 4 (always) that has a total
score range of 0–76, where higher scores indicate greater symptom
severity. The ICG was completed only if the participant selected yes
to the cover sheet question “Have you had an important person in
your life pass away?” The cover sheet included questions about the
relation of important lifetime losses (including spouse, parent, child,
sibling, grandparent, grandchild, other relative, significant other,
partner, fiancé, friend, fellow service member, or other), as well as
which death was the most distressing. The ICG was completed in
relation to this loss. Threshold CG was defined as an ICG score of 30
or higher (Prigerson et al., 1995) at baseline. The term “CG” is used to
represent threshold CG symptoms throughout this paper.
Three additional measures were examined at baseline and
endpoint in relation to threshold CG. The Trauma‐Related Guilt
Inventory (TRGI), a 32‐item (each ranging from 0 to 4, where higher
scores indicate greater symptom severity) questionnaire measuring
cognitive and emotional aspects of guilt associated with the
traumatic event (Kubany et al., 1996), comprises three factors:
global guilt, distress, and guilt cognitions. The Inventory of Functional
Impairment (IFI) is an 80‐item assessment of functional impairment
related to PTSD in seven domains (romantic relationships, family
relationships, work, friendships and socializing, parenting, education,
and self‐care) rated from 0% to 100%, with higher scores represent-
ing greater impairment (Rodriguez, Holowka, & Marx, 2012). Finally,
the clinician‐rated Columbia Suicide Severity Rating Scale (C‐SSRS), a
standardized 10‐point rating assessing a wide spectrum of suicidal
ideation (SI) and behaviors (Posner et al., 2008, 2011), was used to
assess SI and behaviors. We examined two C‐SSRS outcomes during
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treatment: any SI following baseline (n = 170 with post‐baseline
assessments) and worse SI compared to past‐month history at
baseline (i.e., new SI or SI worse than baseline; n = 163 with baseline
and at least one postbaseline assessment).
2.3 | Statistical analyses
All models were run in SAS version 9.4 for Windows. For categorical
outcomes (i.e., treatment response, remission, any and worse SI
during treatment), we used logistic regressions with CG at baseline as
the main predictor of interest. For continuous outcomes measured
over time (i.e., CAPS, TRGI sub‐scales, IFI), we used repeated
measures mixed models with treatment, time (categorical; baseline,
weeks 6, 12, and 24), CG at baseline (yes vs. no), and the interactions
of time by treatment and time by CG as predictors. Time was
modeled as a repeated measure within participant, using an
unstructured covariance matrix to account for the different variances
at each visit and different time‐steps between visits. Consistent with
the primary trial outcome paper (Rauch, Simon, et al., 2018a), all
models were adjusted for site and sex, and all models, except for the
longitudinal CAPS model, were also adjusted for baseline CAPS. The
longitudinal CAPS model retained baseline values as outcomes and
allowed groups to differ at baseline. We used specific contrasts to
test whether the between CG‐group differences observed at baseline
changed at Week 24 (end‐of‐treatment). Means for longitudinal
outcomes are presented as model‐adjusted least‐squares means
(LSM) with 95% confidence intervals, and significance was evaluated
with two‐sided tests using α = 0.05. Effect sizes (d) between groups
were based on LSM differences divided by the pooled standard
deviation of available scores at each time point. In a follow‐up model,
we split the CG group into those who had indicated their most
distressing loss was a fellow service member (n = 25) versus those
who indicated some other loss (n = 21) as most distressing, to
examine the effect of type of loss on CAPS treatment outcome.
Because there were no significant differences between treatment
groups for overall PTSD outcomes (Rauch, Simon, et al., 2018a) and
power was limited, we did not plan significance testing of differential
CG effects on PTSD outcomes by treatment type.
3 | RESULTS
CG was present for 24% (46/194) of participants. The CG sample had a
mean ICG (M±SD) of 40.9 ± 9.0. The non‐CG sample (148/194) included
subjects reporting a loss but no CG (n =108: mean ICG=16.6 ±8.1) plus
those without a reported loss (n= 40). Table 1 describes demographics
and baseline clinical symptom severity. There was some missing data for
select baseline characteristics reported in Table 1: race and ethnicity (no‐
CG=2, CG=0), marital status (no‐CG=2, CG=0), service capacity (no‐
CG=1, CG=0), number of deployments (no‐CG=3, CG=0), service‐
connected disability (no‐CG=1, CG=0), lifetime suicidality (no‐CG=6,
CG=1), and past month suicidality (no‐CG=7, CG=1). Demographics
and military service factors did not differ by presence of CG, with the
exception of ethnicity; Hispanic participants had a lower proportion of
CG (Table 1). The time since the primary loss was 12 or more months
before baseline in 83% of both the CG and non‐CG groups. Loss of a
FSM was reported as the primary most distressing loss by 56% (25/46)
of those with CG, compared to only 27% (29/108) of those with a loss
but no CG. Consistent with our prior baseline report from this study
(Simon et al., 2018), baseline CG was associated with greater PTSD
severity (CAPS), as well as greater trauma‐related guilt (three TRGI sub‐
scales) and functional impairment (Table 2). Suicidal ideation and
behavior did not vary by CG at baseline (Table 1).
3.1 | PTSD response and remission
CG was associated with lower odds of achieving PTSD treatment
response (adjusted odds ratio (AOR) = 0.29, 95% CI [0.12, 0.69],
p = 0.005) or remission (AOR = 0.28, 95% CI [0.11, 0.71], p = 0.007) by
Week 24 (end‐of‐treatment; see Figure 1), after adjusting for site,
sex, and baseline CAPS. Response rates for those with comorbid CG
compared to no‐CG were respectively: 7% (1/15) versus 33% (16/49)
for PE + placebo, 27% (4/15) versus 47% (25/53) for sertraline +
EMM, and 19% (3/16) versus 46% (21/46) for PE + sertraline.
3.2 | Symptom change and endpoint severity with
PTSD treatment
The greater symptom severity associated with CG at baseline
persisted at treatment endpoint for CAPS severity (p = 0.003,
d = 0.57), TRGI global guilt (p < 0.001, d = 0.75), TRGI distress
(p = 0.025, d = 0.43), and TRGI guilt cognitions (p = 0.004, d = 0.53).
Functional impairment with CG was greater at baseline (p = 0.033,
d = 0.35), but not at end‐of‐treatment (p = 0.324, d = 0.18). CG was
not associated with a significant difference in the amount of change
in CAPS (see Figure 2a), TRGI subscales, or IFI over the 24 weeks
(Table 2).
3.3 | Suicidal ideation and CG
There were no baseline differences in lifetime or past month suicidal
ideation (SI) between groups (Table 1). Participants with CG were
more likely to experience some level of SI during the 24 weeks of the
study (OR: 3.01, 95%CI [1.29, 7.02], p = 0.011). There were no
differences in the odds of experiencing worse SI during the treatment
period relative to the month before treatment (26% (10/39) vs. 12%
(15/124); OR: 2.54, 95%CI [0.99, 6.51], p = 0.053). Suicidal behavior
during treatment was rare (3%) in both groups.
3.4 | Impact of loss of a fellow service member
To examine the association of CG with PTSD symptom severity in
greater detail, we split the sample of participants with CG into those
who had CG due to the loss of a FSM (CG‐FSM) and those who had
CG due to non‐FSM losses (CG non‐FSM). In contrast to our
hypotheses, the CG‐FSM sub‐sample was more similar to the no‐CG
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sample in terms of baseline PTSD symptom severity and symptom
change throughout treatment than the CG non‐FSM sub‐sample
(Figure 2b). This appeared to be explained by a greater baseline
PTSD symptom severity in the CG non‐FSM subsample than the no‐
CG sample (p = 0.004, d = 0.69), which persisted throughout
treatment. Baseline PTSD symptom severity in the CG‐FSM sub‐
sample (CAPS: LSM = 62.6, 95%CI [54.8, 70.5]) was intermediate
between the no‐CG sample (LSM = 56.0, 95% CI [52.1, 60.0]) and the
CG non‐FSM subsample (LSM = 74.4, 95% CI [65.5, 83.4]), but did not
differ significantly from either (CG‐FSM vs. no‐CG: p = 0.157,
TABLE 1 Baseline characteristics of treatment seeking post‐9/11 combat veterans with and without comorbid complicated grief
Outcomes No CG (n = 148),M/% (SD/N) CG (n = 46),M/% (SD/N) p < 0.05
Demographics
Age, years, M (SD) 34.6 (8.7) 34 (7.4)
Male gender, % (n) 87 (128) 89 (41)
Race, % (n)
White 61 (89) 52 (24)
Black 27 (39) 37 (17)
Other 12 (18) 11 (5)
Hispanic, % (n) 19 (28) 4 (2) *
High school or less, % (n) 36 (53) 37 (17)
Marital status, % (n)
Single, never married 22 (33) 24 (11)
Married, remarried 52 (76) 54 (25)
Separated, divorced 26 (38) 22 (10)
Widowed 0 (0) 0 (0)
Employment, % (n)
Full‐time 46 (68) 61 (28)
Part‐time 12 (18) 11 (5)
None 42 (62) 28 (13)
Service and disability
Service capacity, most recent, % (n)
Regular armed forces 86 (127) 89 (41)
Reserve unit 3 (4) 4 (2)
National guard 11 (16) 7 (3)
Number of deployments, M (SD) 2.6 (2.8) 2.5 (1.7)
Any disability, % (n) 58 (86) 48 (22)
Service connected disability for PTSD, % (n) 18 (27) 24 (11)
Clinical symptoms
Comorbid MDD, % (n) 66 (98) 78 (36)
Most distressing loss was a FSM, % (n)‡ 27 (29) 56 (25) ***
ICG total score, M(SD)‡ 16.6 (8.1) 40.9 (9.0) ***
Suicidality
Any suicidal ideation, lifetime, % (n) 39 (56) 53 (24)
Any suicidal ideation, past month, % (n) 13 (18) 22 (10)
Any suicidal behavior, lifetime, % (n) 10 (14) 13 (6)
Any suicidal behavior, past 3 months, % (n) 1 (2) 0 (0)
Abbreviations: CAPS, Clinician‐Administered PTSD Scale for DSM‐IV; FSM, fellow service‐member; ICG, Inventory of Complicated Grief; IFI, Inventory of
Functional Impairment; MDD, major depressive disorder; TRGI, Trauma‐Related Guilt Inventory (all sub‐scales are reported as mean scores).
*p < 0.05.
***p < 0.001.
‡Loss type and ICG totals in the no‐CG group are based only on those who were bereaved and completed the ICG (n = 108).
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d = 0.30; CG‐FSM vs. CG non‐FSM: p = 0.214, d = ‐0.36). We similarly
found no difference in the change in PTSD symptoms between the
CG‐FSM subsample and the no‐CG sample (interaction contrast:
p = 0.553; end‐of‐treatment difference: p = 0.203, d = 0.29); by con-
trast, the CG non‐FSM subsample exhibited a significantly smaller
reduction in PTSD symptoms than the no‐CG sample (interaction
contrast: p = 0.023; end‐of‐treatment difference: p = 0.001, d = 1.01).
4 | DISCUSSION
This is the first study to examine the impact of co‐occurring CG on
PTSD outcomes in those receiving evidence‐based PTSD treatment
with sertraline, PE, or their combination. As hypothesized, CG was
associated with significantly lower odds of PTSD treatment response
and remission, after adjustment for baseline PTSD severity (CAPS
score) and other covariates. This appeared to be due to those with CG
having more severe PTSD at baseline. Thus, while participants with
PTSD and comorbid CG had a comparable magnitude of reduction in
PTSD symptoms across treatment during the trial, a higher percentage
of those with CG nonetheless remained above the threshold for PTSD
response or remission at study endpoint. Consistent with this, the CG
group had greater posttreatment PTSD symptom severity and greater
trauma‐related guilt relative to those without CG at endpoint. Further
suggesting comorbid CG is a marker of greater severity, those with CG
were also more likely to experience suicidal ideation during PTSD
treatment compared to those without CG; however, this represented
persistence, not worsening, of SI in the CG group. Given these findings,
TABLE 2 Estimated LSM of PTSD symptom severity, trauma‐related guilt severity, and functional impairment at baseline and end‐of‐
treatment (Week 24) in post‐9/11 combat veterans with and without comorbid CG
No CG CG
Outcome Week LSM 95% CL LSM 95% CL
Pair‐wise
p < 0.05 SDpooled d
Interaction
contrast p
CAPS total scores 0 76.4 [73.0, 79.8] 83.0 [37.2,47.7] 0.005 14.0 0.47 0.079
24 42.4 [78.1, 87.9] 57.2 [48.4, 66.0] 0.003 25.8 0.57
TRGI global guilt 0 1.44 [1.17, 1.71] 2.34 [1.94, 2.74] <0.001 1.16 0.78 0.632
24 0.84 [0.58, 1.10] 1.64 [1.242.04] <0.001 1.07 0.75
TRGI distress 0 2.39 [2.21, 2.57] 2.92 [1.63, 2.05] <0.001 0.80 0.67 0.495
24 1.84 [2.65, 3.19] 2.24 [1.90, 2.58] 0.025 0.94 0.43
TRGI guilt cognition 0 0.78 [0.61, 0.94] 1.22 [0.98, 1.46] <0.001 0.68 0.65 0.566
24 0.59 [0.42, 0.76] 0.96 [0.70, 1.22] 0.004 0.70 0.53
IFI total scores 0 40.3 [37.3, 43.4] 45.3 [40.7, 49.9] 0.033 14.3 0.35 0.417
24 34.9 [31.5, 38.2] 37.5 [32.2, 42.8] 0.324 15.0 0.18
Note: Estimated marginal means were adjusted for treatment type, site, gender, and (for all models except CAPS total scores) CAPS baseline scores in
maximum‐likelihood mixed models. The effect size d is based on LSM differences divided by the raw pooled standard deviation (SDpooled). The interaction
contrast tests whether the no CG vs. CG group difference observed at baseline significantly differs from that at end of treatment (Week 24).
Abbreviations: CG, complicated grief; CL, confidence interval; LSM, least square mean.
F IGURE 1 Association between baseline comorbid complicated grief and treatment response (panel a) and PTSD remission (panel b) in post‐
9/11 combat veterans at the end of 24 weeks of treatment for PTSD. CG, complicated grief; PTSD, posttraumatic stress disorder
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it is unclear why CG was not associated with greater endpoint residual
functional impairment.
The current sample comprises a post‐9/11 combat trauma sample
and as such, these findings should be considered in the context of
prior military grief research. For example, a study of Vietnam
veterans with chronic PTSD suggested that grief is often unad-
dressed and can persist for over 30 years after a combat loss at levels
similar to spousal loss (Pivar & Field, 2004). Papa et al. (2008) have
noted that grief symptoms do not fit in the prevailing fear
conditioning models of PTSD, and that combat losses in particular
may activate survivor guilt and contribute to suicide risk.
In contrast to our hypotheses and prior reports of the impact of
military losses, we found some evidence that CG due to losses that
were not a FSM may be associated with even greater PTSD severity
and be more likely to impair PTSD treatment response as measured
both by the severity of PTSD symptoms at endpoint and the amount
of change in CAPS (see Figure 2b). In other words, while our data
cannot address this directly, CG due to non‐FSM losses could be
acting more similarly to a comorbid condition in worsening PTSD
severity. Additional research is needed to understand how this may
occur, including the effect of non‐FSM losses on social support and
coping with combat related traumas. The higher rate of PTSD
symptom change during treatment seen in veterans with CG due to
FSM losses relative to those with CG due to non‐FSM losses may be
due to a greater overlap between FSM losses and the primary
combat trauma (which patients were directly addressing in PTSD
treatment). In other words, the effects of therapy based on the index
combat trauma may not generalize as well to non‐FSM bereavement.
Although our sample sizes are too low to perform additional analyses
by treatment type, future studies should carefully assess if these
potential explanations may be at play for those in PE specifically.
Those with additional nonmilitary losses and associated CG
symptoms distinct from their index trauma may need additional
intervention to achieve optimal PTSD responses. Importantly, our
findings do not suggest that the loss of a FSM is not impactful; in
contrast, our prior work demonstrated that those with PTSD and the
loss of a FSM have higher CG symptom severity and are more likely
to cross the symptom threshold for CG than those bereaved due to
other causes (Charney et al., 2018; Simon et al., 2018).
It is worth noting that there was a high rate of comorbid major
depressive disorder (MDD) in this population overall, and even
higher (75%) in the CG comorbidity group (Table 1). This is consistent
with prior research suggesting that after traumatic loss there may be
a subgroup of individuals who have high levels of psychiatric
comorbidity and associated distress (e.g., Heeke, Stammel, Heinrich,
& Knaevelsrud, 2017; Simon et al., 2007). Future studies should
examine the effects of comorbid CG with or without MDD on PTSD
as well as on CG treatment outcomes. Additional research on how to
optimally treat comorbid CG, PTSD, and MDD after loss and combat
trauma is needed. For example, the psychotherapy complicated grief
treatment (CGT) has good efficacy for CG despite the high co‐
occurrence of CG with PTSD and MDD (Shear et al., 2016), but its
impact on combat PTSD with comorbid CG is unknown. Overall,
more research is needed to understand the optimal treatment
approaches for enhancing PTSD outcomes in the presence of CG
comorbidity, including whether additional evidence‐based treat-
ments for grief (e.g., Shear, Frank, Houck, & Reynolds, 2005; Shear
at al., 2016; Boelen, de Keijser, van den Hout, & van den Bout, 2007;
Bryant et al., 2014) or other combined approaches for comorbidity
(e.g., Smid et al., 2015) may be needed in addition to trauma focused
work (Papa et al., 2008).
5 | LIMITATIONS
Our study has some limitations. The presence of CG was based solely
on self‐report, using an ICG score of 30 or higher; this is the most
F IGURE 2 Association of baseline comorbid CG with PTSD
symptom severity over time in post‐9/11 combat veterans in
treatment for PTSD. (a) All veterans with CG are combined. (b)
Veterans with CG are split into those who indicated that their most
distressing loss involved a fellow service member (CG‐FSM) and
those whose most distressing loss was not a fellow service member
(CG non‐FSM). Data points for CG groups are nudged to show the
confidence intervals more clearly, and stars above the upper
confidence limits indicate group differences from that group to the
non‐CG group (p < 0.05). CG, complicated grief; FSM, fellow service‐
member; PTSD, posttraumatic stress disorder
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conservative threshold commonly associated with clinical signifi-
cance though lower thresholds have also been used (American
Psychological Association, 2018; Arizmendi, Kaszniak, & O’Connor,
2016; Kersting, Brahler, Glaesmer, & Wagner, 2011; Kersting et al.,
2009; Ott, 2003; Prigerson et al., 2009; Simon et al., 2007). In
addition, because CG was not the primary focus of the parent trial,
we do not have detailed information regarding the nature of the
death (e.g., suicide, combat) or its possible relation to the key
traumatic event reported by participants. We also lack sufficient data
to report the effect of PTSD treatments on CG symptom change or
its correlation with PTSD treatment response. Further, 17% of
primary losses reported occurred less than 12 months before
baseline, suggesting there could be some participants with grief
persisting less than 6 months. Future studies should more closely
examine the time course of effects and whether time since loss and
nature of the death differentially predict PTSD outcomes.
Of interest, while there was some suggestion that there may be
differences in the impact of comorbid CG on PTSD outcomes by type
of treatment, we were underpowered to test this possibility. Finally,
all participants were presenting with a chief complaint of PTSD, not
grief related distress; these data do not address how to best treat
veterans and service members with primary CG.
6 | CONCLUSIONS
CG commonly occurs in service members and veterans with combat
related PTSD. Our data showed lower response and remission rates
in those with comorbid CG relative to those without comorbid CG. In
the parent trial, participants in all three treatment arms improved
significantly and no significant difference in PTSD symptom change
was found by treatment (Rauch, Simon, et al., 2018a). Although our
study was not designed to test for differential treatment outcomes
by CG, our data suggest lower response and remission rates for all
three treatments in those with comorbid CG versus without
comorbid CG. Currently, CG is not routinely screened in military
treatment settings. Our findings add to the growing evidence that
such screening may be warranted (e.g., Currier & Holland, 2012; Papa
et al., 2008; Toblin et al., 2012) along with additional research on
how to optimally treat PTSD with CG comorbidity.
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